Bank of New York Mellon
EBS icon

Bank of New York Mellon’s Emergent Biosolutions EBS Stock Holding History

Bank of New York Mellon’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-190
Closed -$4K – 4202
2013
Q4 		$4K Hold
190
– – ﹤0.01% 4196
2013
Q3 		$4K Buy
+190
New +$3.39K ﹤0.01% 4146

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1.16B AUM 53.61% 1-Year Est. Return

Bank of New York Mellon's EBS Position: Q2 2026 in Review

Bank of New York Mellon increased its Emergent Biosolutions (EBS) stake by 2.1% in Q2 2026, buying an estimated $38.6K and bringing the position to 219,661 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2997.

Bank of New York Mellon first reported a position in EBS in Q2 2013 and has held it in 52 quarters since. The position peaked at $91.2M in Q2 2015. 107 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Bank of New York Mellon held 219,661 shares of Emergent Biosolutions worth $1.84M as of Q2 2026.
  • Bank of New York Mellon bought 4,618 Emergent Biosolutions shares in Q2 2026, an estimated $38.6K.
  • Emergent Biosolutions made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2997 holding.
  • Bank of New York Mellon first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 52 quarters since.
  • Bank of New York Mellon's Emergent Biosolutions position peaked at $91.2M in Q2 2015.
  • 107 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.